Back to top
more

Addus HomeCare (ADUS)

(Delayed Data from NSDQ)

$94.54 USD

94.54
205,950

+2.84 (3.10%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $94.49 -0.05 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (151 out of 252)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Neogen (NEOG) Launches Genomic Test for Beef-on-Dairy Calves

by Zacks Equity Research

Neogen's (NEOG) new Igenity BeefXDairy test is an additional tool, enabling producers to gather crucial data they need to advance and grow their operations effectively and sustainably.

Thermo Fisher's (TMO) Unveils Orbitrap Astral Spectrometer

by Zacks Equity Research

Thermo Fisher's (TMO) OrbitrapTM AstralTM mass spectrometer enables accurate and exact quantification in proteomics laboratories.

Hologic (HOLX) Stock Up 5.6% YTD: Will the Rally Continue?

by Zacks Equity Research

The higher capital equipment revenues, procedural volumes return and an acceleration from the new business lines poise Hologic (HOLX) for future growth.

Here's Why You Should Hold on to Align Technology (ALGN) Now

by Zacks Equity Research

Investors are optimistic about Align Technology (ALGN) owing to expanding work-flow options of its leading iTero scanners.

ADUS or USPH: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ADUS vs. USPH: Which Stock Is the Better Value Option?

Illumina's (ILMN) New AI Tool to Predict Genomics Disease

by Zacks Equity Research

Illumina's (ILMN) PrimateAI-3D will be made broadly available to the genomics community integrated across Illumina Connected Software.

Haemonetics (HAE) Hospital Arm Grows, Plasma Volume Improves

by Zacks Equity Research

Within Haemonetics (HAE) Vascular Closure, growth is led by the opening of new accounts and increasing penetration to gain share in the top U.S. EP hospitals.

Charles River (CRL) to Build RightSource Lab With New Pact

by Zacks Equity Research

Charles River (CRL) will establish a CGMP testing lab at Wheeler's factory through latest partnership.

Bio-Rad (BIO) Faces Macroeconomic Headwinds, Rising Expenses

by Zacks Equity Research

Bio-Rad's (BIO) process chromatography business witnesses a slowdown in the quarter due to tough comparisons and some softness in the bioprocessing market.

Here's Why You Should Invest in Haemonetics (HAE) Right Now

by Zacks Equity Research

Investors are optimistic about Haemonetics (HAE), led by the impressive performance of Plasma and Hospital businesses.

Boston Scientific (BSX) Rises 26.4%: Will the Rally Continue?

by Zacks Equity Research

Boston Scientific (BSX) gains from strong improvement in organic sales, indicating a solid rebound in the legacy business.

Wall Street Analysts Predict a 28.56% Upside in Addus HomeCare (ADUS): Here's What You Should Know

by Zacks Equity Research

The mean of analysts' price targets for Addus HomeCare (ADUS) points to a 28.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Medtronic (MDT) to Expand Diabetes Care With New Buyout

by Zacks Equity Research

Medtronic's (MDT) latest acquisition will increase its capacity to assist more individuals with diabetes worldwide within a single, seamless Medtronic support ecosystem.

Here's Why You Should Retain CVS Health (CVS) Stock for Now

by Zacks Equity Research

Investors are optimistic about CVS Health (CVS) on continued growth across the entire range of insured and self-insured medical, pharmacy, dental and behavioral health products and services.

Thermo Fisher (TMO) Expands Manufacturing Facility in APAC

by Zacks Equity Research

Thermo Fisher (TMO) latest expansion will enable it to better assist clients in accelerating their research, development and marketing of medications and vaccines in the Asia-Pacific region.

Here's Why Investors Should Add Zimmer Biomet (ZBH) Now

by Zacks Equity Research

Investors are optimistic about Zimmer Biomet (ZBH) on continued procedure recovery, solid execution and increasing traction around innovations.

QIAGEN (QGEN) Expands Enzyme Offering to Aid Laboratory

by Zacks Equity Research

QIAGEN is a one-stop shop for all research needs, including solutions for sample preparation, automation and bioinformatics with enzyme offering expansion.

National Vision (EYE) Plans to Open New Stores Amid Macro Woes

by Zacks Equity Research

National Vision (EYE) plans to continue executing core growth initiatives and further investing in competitive advantages.

Abbott (ABT) Expands in Electrophysiology With New FDA Nod

by Zacks Equity Research

Abbott (ABT) notes that using TactiFlex catheter can lead to reduced procedure times and better safety compared to the company's previous generation catheters.

Hologic (HOLX) Gets FDA Nod for Multiplexed Respiratory Test

by Zacks Equity Research

Hologic's (HOLX) Panther Fusion SARS-CoV-2/Flu A/B/RSV assay is done using the fully-automated, high-throughput Panther Fusion system.

Abbott's (ABT) Assert-IQ Cardiac Monitor Receives FDA Approval

by Zacks Equity Research

Abbott's (ABT) latest approval adds to its line-up of remote patient management and treatment tools that can support doctors more effectively.

STERIS (STE) Continues to Face Dull Dental Sales, Margin Woes

by Zacks Equity Research

STERIS (STE) competes for pharmaceutical, research and industrial customers against several large companies that have robust product portfolios and global reach.

Edwards Lifesciences' (EW) TAVR Study Outcome Favorable

by Zacks Equity Research

Edwards Lifesciences' (EW) latest findings of the study confirm the value of the Edwards Benchmark programme for standardizing clinical pathways for patients undergoing TAVR in Europe.

Here's Why Investors Should Retain Omnicell (OMCL) Stock Now

by Zacks Equity Research

Investors are optimistic about Omnicell (OMCL) on its strong execution of strategies, disciplined cost management and revenue timing.

ADUS vs. USPH: Which Stock Is the Better Value Option?

by Zacks Equity Research

ADUS vs. USPH: Which Stock Is the Better Value Option?